Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient's perspective shortly (2 to 4 weeks) after initiation...

Full description

Saved in:
Bibliographic Details
Main Authors: Alice B. Gottlieb (Author), Russel Burge (Author), William N. Malatestinic (Author), Baojin Zhu (Author), Yunyang Zhao (Author), Julie McCormack (Author), Miriam Kimel (Author), Joseph F. Merola (Author)
Format: Book
Published: Adis, Springer Healthcare, 2023-07-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items